Medicare Covers CBD Without FDA Approval and Faces a Lawsuit
Medicare CBD policy regulatory access is evolving as coverage occurs without FDA approval, prompting legal challenges. This shift affects patient access and insurance reimbursement for CBD products. Clinicians must monitor these developments closely to…
Texas Bans Smokable Hemp Cannabis Products – Clinical Impact
The Texas smokable hemp ban restricts inhalation delivery of hemp-derived cannabinoids, affecting patient access. This regulatory change forces clinicians to consider alternative delivery methods. Patients must adapt to new options for symptom management…
Exploring Neuroprotective Cannabis Clinical Trials and Their Impact
Neuroprotective cannabis clinical trials are advancing research into treatments for neurological disorders. These trials explore cannabis compounds' potential to protect nerve cells. Understanding clinical evidence helps guide safe and effective use.
Judge Denies SAM’s Temporary Restraining Order; CBD Pilot Program Launches
CBD pilot programs represent controlled opportunities to generate real-world safety and efficacy data under regulatory oversight. A judge has denied SAM's request for a temporary restraining order, allowing the CBD pilot program to proceed. These…
PharmDs Explain What Happens When You Mix CBD and Alcohol Together
Pharmacokinetic interactions CBD alcohol can affect how both substances are metabolized in the liver. Patients often combine CBD and alcohol without understanding potential risks. This article highlights clinical effects and safety considerations for…
High Tide Subsidiary NuLeaf Naturals Pursues Medicare CBD Pilot Program
Medicare CBD insurance coverage is gaining attention as NuLeaf Naturals pursues participation in a new pilot program. This development could transform access to CBD for millions of older adults. The pilot represents a potential shift in federal insurance…
High Tide Subsidiary NuLeaf Naturals Pursues Participation in U.S. Medicare CBD Pilot
Medicare CBD insurance coverage policy is evolving with a new pilot program including NuLeaf Naturals. This initiative marks a significant step toward federal recognition of cannabis therapeutics. It could improve access for Medicare beneficiaries facing…
Missouri AG Sues CBD American Shaman Over Kratom Products – KFVS12
Missouri Attorney General sues CBD American Shaman over kratom products, raising important regulatory and patient safety issues. This lawsuit highlights the challenges in overseeing CBD and kratom sales. Patients and clinicians should be aware of the…
Marijuana Rescheduling Foes File First Lawsuit, Target Trump CBD Promise
The marijuana rescheduling lawsuit challenges federal cannabis policy and CBD access. This legal battle affects medical cannabis prescribing authority and patient treatment continuity. Clinicians and patients should stay informed about these evolving…
Understanding New Hemp Regulatory Changes
Hemp regulatory changes directly impact product availability, quality standards, and legal clarity for patients using CBD and hemp-derived cannabinoids. Clinicians must understand evolving compliance requirements to guide patient access effectively.…